Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women

Clinical Pharmacokinetics

Volumn 51, Issue 11, 2012, Pages 743-749

  De Oliveira Baraldi, Cláudia ^a   Moisés, Elaine C D ^a   De Jesus Ponte Carvalho, Teresa M ^a   De Jesus Antunes, Natalícia ^a   Lanchote, Vera L ^a   Duarte, Geraldo ^a   Cavalli, Ricardo Carvalho ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; STEADY STATE; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; YOUNG ADULT;

EID: 84873434671     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0008-7     Document Type: Article

References (35)

1. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-72.
2. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9.
3. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol. 1999;94:194-7.
4. Mikola M, Hiilesman V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:226-9.
5. Bjercke S, Dale PO, Tanbo T, et al. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest. 2002;54:94-8.
6. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691-6.
7. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139-46.
8. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:2767-74.
9. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:569-74.
10. Balani J, Hyer SL, Rodin DA, Shehata H. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med. 2009;26(8):798-802.
11. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf. 2007;6(2):191-8.
12. Ghazeeri GS, Nassar AH, Younes Z, Awwad JT. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand. 2012;91(6):658-78.
13. Khattab S, Mohsen IA, Aboul Foutouh I, Ashmawi HS, Mohsen MN, van Wely M, et al. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol Endocrinol. 2011;27(10):789-93.
14. De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):63-6.
15. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23:545-51.
16. Song IS, Shin HJ, Sim EJ, et al. Genetic variants of organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559-62.
17. Moreno-Navarrete JM, Ortega FJ, Rodríguez-Hermosa JI, Sabater M, Pardo G, Ricart W, et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011;60(1):168-76.
18. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.
19. Baraldi de Oliveira C, Lanchote VL, Antunes de Jesus N, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027-33.
20. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235-46.
21. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med. 2004;21:829-36.
22. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75:46-52.
23. Boomsma CM, Eijkemans MJC, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-83.
24. Tertti K, Ekblad U, Vahlberg T, Rönnemaa T. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud. 2008;5(2):95-101.
25. Carles G, Germain L, Alassas N, et al. Treatment of gestational diabetes with oral hypoglycemic agents. J Gynecol Obstet Biol Reprod. 2010;39(2):139-43.
26. Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol. 1999;93:858-68.
27. Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328-43.
28. Arafat T, Kaddoumi A, Shami M. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther. 1944;11:21-33.
29. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359-71.
30. Qaisi AM, Tutunji MF, Sahouri CA. Determination of metformin in human plasma using normal phase high performance liquid chromatography. Saudi Pharm J. 2006;14(2):108-14.
31. Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38(5):833-40.
32. Wang Y, Tang Y, Gu J, et al. Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantitation of metformin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;808(2):215-9.
33. Chen X, Gu Q, Qiu F, et al. Rapid determination of metformin in human plasma by liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;802(2):377-81.
34. Hughes RC, Gardiner SJ, Begg EJ, et al. Effect of pregnancy on the pharmacokinetics of metformin. Diabet Med. 2006;23(3):323-6.
35. Rowan JA, Gao W, Hague WM, et al. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. Diabetes Care. 2010;33(1):9-16.